1. Agency EM (2010) Guideline on the investigation of bioequivalence. In: Agency EM (Hrsg). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf
2. Agency EM (1995) Note for guidance on the clinical requirements for locally applied, locally acting products containing known constituents. European Medicines Agency. http://ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003687.pdf, S 4
3. Allaire C, Dietrich A, Allmeier H et al (2012) Latanoprost 0.005 % test formulation is as effective as Xalatan® in patients with ocular hypertension and primary open-angle glaucoma. Eur J Ophthalmol 22:19–27
4. Almuzaini T, Choonara I, Sammons H (2013) Substandard and counterfeit medicines: a systematic review of the literature. BMJ Open 3:e002923
5. Roche.de (2013) Informationen für Patienten: Aussehen der Roche-Fertigspritze Pegasys. Roche Deutschland Holding GmbH. http://www.roche.de/presse/meldungen/Informationen-fuer-Patienten-Aussehen-der-Original-Fertigspritze-Pegasyssupsup-3464. html?sid=01e4b1cedbb57fc42687f171747b77d3&bereich=Alle